Carnegie Investment Counsel Sells 27,820 Shares of Novo Nordisk A/S $NVO

Key Points

• Carnegie Investment Counsel trimmed its Novo Nordisk stake by 10.2% in Q4, selling 27,820 shares and leaving it with 245,049 shares worth about $12.47 million.
• Novo Nordisk is seeing mixed catalysts: regulatory and product wins for Wegovy (improved storage rules and an expanding oral option) but rising competitive pressure from Eli Lilly’s oral GLP‑1 and reports of cheap semaglutide generics, with analysts warning Q1 will be a key read on pricing and near‑term earnings risk.
• The company recently reported an earnings beat (Q4 EPS $1.01 vs. $0.90; revenue $12.43B vs. $11.97B), yet shares trade well below last year’s highs and consensus Street coverage is currently centered around a Hold rating.

Carnegie Investment Counsel lessened its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 10.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 245,049 shares of the company's stock after selling 27,820 shares during the period. Carnegie Investment Counsel's holdings in Novo Nordisk A/S were worth $12,468,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. True Wealth Design LLC raised its position in shares of Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company's stock worth $25,000 after purchasing an additional 300 shares during the last quarter. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth about $25,000. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $28,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. Finally, Strengthening Families & Communities LLC purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth about $30,000. Institutional investors own 11.54% of the company's stock.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Short interest fell sharply in March (about a 19% drop vs. mid‑March), lowering near‑term bearish pressure and reducing potential short‑covering risk. (Source: recent short‑interest report)
• Positive Sentiment: EMA cleared an update allowing Wegovy injections to be delivered at up to 30°C for 48 hours, which should improve distribution flexibility and lower logistics costs in Europe — a modest operational tailwind. Wegovy EMA approval
• Positive Sentiment: Wegovy’s oral formulation appears to be expanding the obesity treatment market by drawing new patients (not just switching injection users), supporting longer‑term demand potential for Novo’s GLP‑1 franchise. CNBC short on Wegovy pill
• Neutral Sentiment: Positive buy‑and‑hold coverage and listings naming Novo as a top growth stock provide long‑term investor support but do not address near‑term competitive or pricing issues. Yahoo piece on growth thesis
• Neutral Sentiment: Novo Holdings (the controlling shareholder) is adding investments outside pharma (e.g., superconductors), which is a corporate/portfolio move with limited direct impact on Novo Nordisk’s operational outlook. Novo Holdings investment
• Negative Sentiment: Eli Lilly launched its once‑daily oral GLP‑1 (Foundayo) broadly in the U.S., increasing competitive pressure on Novo’s market share and pricing power in weight‑loss treatments. Foundayo availability
• Negative Sentiment: Reports of cheap semaglutide generics in India are eroding pricing power in key markets and could weigh on longer‑term revenue if generics expand beyond regional markets. India generics report
• Negative Sentiment: UBS and other analysts warn Q1 results (May 6) will be the first meaningful read on economics at new, lower GLP‑1 price points; coupled with a disappointing CagriSema trial and below‑consensus 2026 guidance earlier this year, this raises near‑term earnings risk. UBS pricing test note
• Negative Sentiment: Media and commentators highlight Eli Lilly pulling ahead in the obesity drug race, which can weigh on sentiment and relative valuation for Novo in the near term. 247WallSt comparison

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $37.52 on Friday. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $81.44. The business has a 50-day simple moving average of $41.03 and a two-hundred day simple moving average of $49.06. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $167.51 billion, a price-to-earnings ratio of 10.81, a price-to-earnings-growth ratio of 8.83 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. On average, analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which was paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th were given a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S's payout ratio is 50.43%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NVO. Zacks Research raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research report on Monday, March 2nd. Nordea Equity Research lowered Novo Nordisk A/S to a "hold" rating in a research report on Tuesday, February 24th. Sanford C. Bernstein began coverage on Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price target for the company. Finally, BMO Capital Markets reaffirmed a "market perform" rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Four analysts have rated the stock with a Buy rating and twenty have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.